已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial

医学 改良兰金量表 冲程(发动机) 临床试验 不利影响 移植 随机对照试验 临床终点 人口 外科 内科学 缺血性中风 缺血 机械工程 环境卫生 工程类
作者
Francisco Moniche,Juan Antonio Cabezas-Rodriguez,Roberto Valverde,Irene Escudero‐Martínez,Lucia Lebrato-Hernandez,Blanca Pardo‐Galiana,L. Ainz,Manuel Medina-Rodríguez,Javier de la Torre,Virginia Escamilla Gómez,Joaquín Ortega-Quintanilla,Elena Zapata‐Arriaza,Asier de Albóniga-Chindurza,Fernando Mancha,Miguel Ángel Gamero-García,Soledad Perez,Raul Espinosa-Rosso,Lucia Forero-Diaz,Miguel Moya,Pilar Piñero
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:22 (2): 137-146 被引量:31
标识
DOI:10.1016/s1474-4422(22)00526-9
摘要

Pilot clinical trials have shown the safety of intra-arterial bone marrow mononuclear cells (BMMNCs) in stroke. However, the efficacy of different doses of intra-arterial BMMNCs in patients with acute stroke has not been tested in a randomised clinical trial. We aimed to show safety and efficacy of two different doses of autologous intra-arterial BMMNC transplantation in patients with acute stroke.The IBIS trial was a multicentre phase 2, randomised, controlled, investigator-initiated, assessor-blinded, clinical trial, in four stroke centres in Spain. We included patients (aged 18-80 years) with a non-lacunar, middle cerebral artery ischaemic stroke within 1-7 days from stroke onset and with a National Institutes of Health Stroke Scale score of 6-20. We randomly assigned patients (2:1:1) with a computer-generated randomisation sequence to standard of care (control group) or intra-arterial injection of autologous BMMNCs at one of two different doses (2 × 106 BMMNCs/kg or 5 × 106 BMMNCs/kg). The primary efficacy outcome was the proportion of patients with modified Rankin Scale scores of 0-2 at 180 days in the intention-to-treat population, comparing each BMMNC dose group and the pooled BMMNC group versus the control group. The primary safety endpoint was the proportion of serious adverse events. This trial was registered at ClinicalTrials.gov, NCT02178657 and is completed.Between April 1, 2015, and May 20, 2021, we assessed 114 patients for eligibility. We randomly assigned 77 (68%) patients: 38 (49%) to the control group, 20 (26%) to the low-dose BMMNC group, and 19 (25%) the high-dose BMMNC group. The mean age of participants was 62·4 years (SD 12·7), 46 (60%) were men, 31 (40%) were women, all were White, and 63 (82%) received thrombectomy. The median NIHSS score before randomisation was 12 (IQR 9-15), with intra-arterial BMMNC injection done a median of 6 days (4-7) after stroke onset. The primary efficacy outcome occurred in 14 (39%) patients in the control group versus ten (50%) in the low-dose group (adjusted odds ratio 2·08 [95% CI 0·55-7·85]; p=0·28), eight (44%) in the high-dose group (1·89 [0·52-6·96]; p=0·33), and 18 (47%) in the pooled BMMNC group (2·22 [0·72-6·85]; p=0·16). We found no differences in the proportion of patients who had adverse events or dose-related events, but two patients had a groin haematoma after cell injection in the low-dose BMMNC group.Intra-arterial BMMNCs were safe in patients with acute ischaemic stroke, but we found no significant improvement at 180 days on the mRS. Further clinical trials are warranted to investigate whether improvements might be possible at different timepoints.Instituto de Salud Carlos III co-funded by the European Regional Development Fund/European Social Fund, Mutua Madrileña, and the Regional Ministry of Health of Andalusia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
keep发布了新的文献求助10
1秒前
2秒前
Lvsh完成签到,获得积分10
3秒前
4秒前
科研通AI6.3的应助被贪玩飞珍采纳,获得10
5秒前
mmmmm完成签到,获得积分10
5秒前
6秒前
小二郎的应助被明理的晓筠采纳,获得30
7秒前
英姑的应助被啊唔采纳,获得10
7秒前
张zhang完成签到,获得积分10
8秒前
落寞绝音完成签到,获得积分10
8秒前
阎听筠完成签到 ,获得积分10
11秒前
落寞绝音发布了新的文献求助10
11秒前
12秒前
li完成签到 ,获得积分10
13秒前
科目三的应助被ZeyG采纳,获得10
17秒前
啊唔发布了新的文献求助10
18秒前
Panxy完成签到,获得积分10
18秒前
xx关闭了xx的文献求助
19秒前
20秒前
ding的应助被圈圈采纳,获得10
20秒前
20秒前
21秒前
2026221709发布了新的文献求助10
23秒前
23秒前
清爽的初之完成签到,获得积分10
23秒前
111发布了新的文献求助10
25秒前
26秒前
金箍棒发布了新的文献求助20
26秒前
27秒前
辛勤枫叶完成签到,获得积分10
27秒前
可爱的函函的应助被尊嘟假嘟采纳,获得10
27秒前
斯文败类的应助被尊嘟假嘟采纳,获得10
27秒前
Jasper的应助被尊嘟假嘟采纳,获得10
28秒前
华仔的应助被尊嘟假嘟采纳,获得10
28秒前
今后的应助被尊嘟假嘟采纳,获得10
28秒前
万能图书馆的应助被尊嘟假嘟采纳,获得10
28秒前
JiaYouguo发布了新的文献求助60
28秒前
Lucas的应助被尊嘟假嘟采纳,获得10
28秒前
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184595
求助须知:如何正确求助?哪些是违规求助? 9573554
关于积分的说明 21832227
捐赠科研通 7781812
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558490
邀请新用户注册赠送积分活动 2480994